Reem Karmali – Grants — Northwestern Scholars

View Scopus Profile

Emailreem.karmalinorthwesternedu

Research activity per year

If you made any changes in Pure these will be visible here soon.

6 Finished
18 Active

6 results

Filter

Finished

Prot #13676-01: A Phase 1 Multidose Study To Evaluate The Safety And Tolerability Of XmAb®13676 In Patients With Cd20-Expressing Hematologic Malignancies
Karmali, R.
Chiltern International, Inc., Xencor, Inc.
9/1/17 → 9/1/20
Project: Research project
Impact of Cachexia on Clinical Outcomes in Aggressive Lymphomas
Karmali, R.
Lymphoma Research Foundation
9/1/16 → 6/15/19
Project: Research project
Prot #INCB 52793-101: A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies
Karmali, R. & Kaplan, J. B.
Parexel, Incyte Corporation
12/2/15 → 12/2/18
Project: Research project
Prot #INCB 54329-101: Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies
Karmali, R. & Kaplan, J. B.
Covance Inc., Incyte Corporation
9/11/15 → 9/11/18
Project: Research project
Prot #KCP-330-009: A Phase 2b Open-label, Randomized Two-arm Study of Selinexor (KPT-330) with Low Dose Dexamethasone in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Karmali, R. & Kaplan, J. B.
Clinipace, Inc., Karyopharm Therapeutics Inc.
12/23/14 → 12/23/20
Project: Research project
Prot #CC-122-DLBCL-001: A Phase 1B, Multi-Center, Open Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma
Karmali, R. & Kaplan, J. B.
Celgene Corporation
9/17/13 → 9/17/19
Project: Research project